Author Correction: Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?

abstract：:Therapeutic drug monitoring is now widely used in many areas of medicine. With its proliferation has come an understanding of the clinical situations in which it is likely to be of value. Factors that can limit the usefulness of therapeutic drug monitoring and situations where it is less likely to be of benefit have a...

journal_title：Clinical pharmacokinetics

authors： Moore MJ,Erlichman C

更新日期：1987-10-01 00:00:00

abstract：BACKGROUND:Enzyme replacement therapy (ERT) is currently the standard treatment for patients with Gaucher disease type I (GD1), but the pharmacokinetics have hardly been studied. This study aimed to quantify in vivo enzyme activity in peripheral leukocytes from patients receiving long-term treatment with imiglucerase o...

journal_title：Clinical pharmacokinetics

authors： Gras-Colomer E,Martínez-Gómez MA,Moya-Gil A,Fernandez-Zarzoso M,Merino-Sanjuan M,Climente-Martí M

更新日期：2016-09-01 00:00:00

abstract：OBJECTIVE:To analyse the influence of covariates on the apparent clearance (CL) of tacrolimus in paediatric liver transplant recipients being converted from cyclosporin to tacrolimus. DESIGN:Retrospective modelling study. PATIENTS AND PARTICIPANTS:18 children, 13 girls and 5 boys, aged 4 months to 16 years (median 9....

journal_title：Clinical pharmacokinetics

authors： García Sánchez MJ,Manzanares C,Santos-Buelga D,Blázquez A,Manzanares J,Urruzuno P,Medina E

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and pulsatile growth hormone (GH) secretion and subsequently increases insulin-like growth factor (IGF)-1. Limited information is available about the pharmacokinetics of this compound. Consequen...

journal_title：Clinical pharmacokinetics

authors： González-Sales M,Barrière O,Tremblay PO,Nekka F,Mamputu JC,Boudreault S,Tanguay M

更新日期：2015-03-01 00:00:00

abstract：:Uncertainty exists as to the most suitable pharmacokinetic parameter sets for propofol target-controlled infusions (TCI). The pharmacokinetic parameter sets currently employed are clearly not universally applicable, particularly when patient attributes differ from those of the subjects who participated in the original...

journal_title：Clinical pharmacokinetics

authors： Coetzee JF

更新日期：2012-03-01 00:00:00

abstract：:Escitalopram is the (S)-enantiomer of the racemic selective serotonin reuptake inhibitor antidepressant citalopram. Clinical studies have shown that escitalopram is effective and well tolerated in the treatment of depression and anxiety disorders. Following oral administration, escitalopram is rapidly absorbed and rea...

journal_title：Clinical pharmacokinetics

authors： Rao N

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Daclatasvir is a potent, pangenotypic once-daily hepatitis C virus (HCV) NS5A inhibitor that is approved for the treatment of chronic HCV infection. The objective of this analysis was to characterize the pharmacokinetics of daclatasvir in subjects with chronic HCV infection. METHODS:A populati...

journal_title：Clinical pharmacokinetics

authors： Chan P,Li H,Zhu L,Bifano M,Eley T,Osawa M,Ueno T,Hughes E,Bertz R,Garimella T,AbuTarif M

更新日期：2017-10-01 00:00:00

abstract：:Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a reduction of aqueous humour production and the...

journal_title：Clinical pharmacokinetics

authors： Martens-Lobenhoffer J,Banditt P

更新日期：2002-01-01 00:00:00

abstract：:In the past decade, fludarabine has had a major impact in increasing the effectiveness of treatment of patients with indolent B-cell malignancies. This has come about in a variety of clinical circumstances, including use of fludarabine alone as well as in combinations with DNA-damaging agents or membrane-targeted anti...

journal_title：Clinical pharmacokinetics

authors： Gandhi V,Plunkett W

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Entecavir is an orally administered guanosine nucleoside analog with activity against hepatitis B virus (HBV) polymerase, which is approved for the treatment of chronic hepatitis B (CHB) infection in adults and children ≥2 years old (USA and EU). OBJECTIVE:To develop simplified entecavir dosing recommendati...

journal_title：Clinical pharmacokinetics

authors： Chan P,Mould DR,Tarif MA,Reynolds L,LaCreta F,Bertz R,Bifano M

更新日期：2016-12-01 00:00:00

abstract：:Due to concern and debate in the epilepsy medical community and to the current interest of the US Food and Drug Administration (FDA) in revising approaches to the approval of generic drugs, the FDA is currently supporting ongoing bioequivalence studies of antiepileptic drugs, the EQUIGEN studies. During the design of ...

journal_title：Clinical pharmacokinetics

authors： Diaz FJ,Berg MJ,Krebill R,Welty T,Gidal BE,Alloway R,Privitera M

更新日期：2013-12-01 00:00:00

abstract：:Analogues of human insulin have been developed to more closely replicate the physiology of meal-related and basal insulin secretion. Three rapid-acting analogues and two basal analogues are available for clinical use. Insulin aspart and insulin lispro have nearly identical pharmacokinetic and pharmacodynamic profiles ...

journal_title：Clinical pharmacokinetics

authors： Roach P

更新日期：2008-01-01 00:00:00

abstract：:Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due to its stereoselective pharmacokinetics. I...

journal_title：Clinical pharmacokinetics

authors： Brocks DR,Jamali F

更新日期：1994-04-01 00:00:00

abstract：:Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the 2,6-disubstituted naphthyl-alkanone class. Nabumetone is metabolised to an active metabolite 6-methoxy-2-napthylacetic acid (6-MNA) which is a relatively selective cyclo-oxygenase-2 inhibitor that has anti-inflammatory and analgesic properties. Nabumet...

journal_title：Clinical pharmacokinetics

authors： Davies NM

更新日期：1997-12-01 00:00:00

abstract：BACKGROUND:Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis. METHODS:This analysis characterizes the population pharmacokinetics of subcutaneous tildrakizumab and identifies covariates influencing exposure in 2098 healthy volunteers and subj...

journal_title：Clinical pharmacokinetics

authors： Jauslin P,Kulkarni P,Li H,Vatakuti S,Hussain A,Wenning L,Kerbusch T

更新日期：2019-08-01 00:00:00

abstract：:The results of research studies conducted to date in vitro and in healthy volunteers are practically all concordant in demonstrating the lack of any kind of interference between famotidine and microsomal oxidative metabolism. The pharmacokinetics (elimination half-life, area under the plasma concentration-time curve, ...

journal_title：Clinical pharmacokinetics

authors： Dal Negro R,Pomari C,Turco P

更新日期：1993-03-01 00:00:00

abstract：OBJECTIVE:The objective of this analysis was to simulate the performance of oral triptan formulations with varying absorption characteristics and their impact on the onset and magnitude of the antimigraine effect using a Markov model for migraine attacks. ANALYSIS:Sumatriptan pharmacokinetic data were obtained from cl...

journal_title：Clinical pharmacokinetics

authors： Maas HJ,Spruit MA,Danhof M,Della Pasqua OE

更新日期：2008-01-01 00:00:00

abstract：:Adequate immunosuppression minimising the risk of organ rejection with acceptable tolerability of the used drugs is a crucial step in organ transplantation. The primary goal is to maintain a consistent time-dependent target concentration by tailoring individual dosage leading to the best efficacy and tolerability comb...

journal_title：Clinical pharmacokinetics

authors： Mourad M,Wallemacq P,König J,de Frahan EH,Eddour DC,De Meyer M,Malaise J,Squifflet JP

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Fondaparinux sodium is a novel antithrombotic agent, the first of a new class of selective factor Xa inhibitors. It has favourable pharmacokinetics including 100% bioavailability, low variability and a mean terminal half-life of 17 hours for young and 21 hours for elderly healthy volunteers, enabling once-da...

journal_title：Clinical pharmacokinetics

authors： Paolucci F,Claviés MC,Donat F,Necciari J

更新日期：2002-01-01 00:00:00

abstract：:The pharmacokinetics of metoprolol have been studied in a group of patients with varying degrees of renal impairment and in healthy subjects after administration of 20 mg of metoprolol tartrate intravenously and 50 mg orally in a single dose and during steady-state conditions. There were no significant differences in ...

journal_title：Clinical pharmacokinetics

authors： Jordö L,Attman PO,Aurell M,Johansson L,Johnsson G,Regårdh CG

更新日期：1980-03-01 00:00:00

abstract：:Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. They are proposed as a novel approach for the management of type 2 diabetes mellitus. They have proven their efficacy in reducing glycated haemoglobin...

journal_title：Clinical pharmacokinetics

authors： Scheen AJ

更新日期：2014-04-01 00:00:00

abstract：:Few of the articles published on antibiotics and pregnancy are concerned with pharmacokinetics. It is particularly difficult to evaluate possible alterations in pharmacokinetic parameters that may be due to pregnancy. Most data available have been obtained in connection with abortion or delivery. Such data may not be ...

journal_title：Clinical pharmacokinetics

authors： Philipson A

更新日期：1979-07-01 00:00:00

abstract：:The ability to deliver safe and effective moderate sedation is crucial to the ability to perform invasive procedures. Sedative drugs should have a quick onset of action, provide rapid and clear-headed recovery, and be easy to administer and monitor. A number of drugs have been demonstrated to provide effective sedatio...

journal_title：Clinical pharmacokinetics

authors： Gan TJ

更新日期：2006-01-01 00:00:00

abstract：:Cisapride, a prokinetic agent, has been used for the treatment of a number of gastrointestinal disorders, particularly gastro-oesophageal reflux disease in adults and children. Since 1993, 341 cases of ventricular arrhythmias, including 80 deaths, have been reported to the US Food and Drug Administration. Marketing of...

journal_title：Clinical pharmacokinetics

authors： Michalets EL,Williams CR

更新日期：2000-07-01 00:00:00

abstract：:The present article should be read in conjunction with the original review published in the Journal in 1983. There is no new information of major significance about the pharmacokinetics of levonorgestrel, norethisterone (norethindrone) or ethinylestradiol, although it has been shown that the concentrations of these ho...

journal_title：Clinical pharmacokinetics

authors： Shenfield GM,Griffin JM

更新日期：1991-01-01 00:00:00

abstract：BACKGROUND:The imatinib trough plasma concentration (C(min)) correlates with clinical response in cancer patients. Therapeutic drug monitoring (TDM) of plasma C(min) is therefore suggested. In practice, however, blood sampling for TDM is often not performed at trough. The corresponding measurement is thus only remotely...

journal_title：Clinical pharmacokinetics

authors： Gotta V,Widmer N,Montemurro M,Leyvraz S,Haouala A,Decosterd LA,Csajka C,Buclin T

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Hydroxychloroquine is an oral drug prescribed to pregnant women with rheumatic disease to reduce disease activity and prevent flares. Physiologic changes during pregnancy may substantially alter drug pharmacokinetics. However, the effect of pregnancy on hydroxychloroquine disposition and the potential need f...

journal_title：Clinical pharmacokinetics

authors： Balevic SJ,Green TP,Clowse MEB,Eudy AM,Schanberg LE,Cohen-Wolkowiez M

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Two phase I drug interaction studies were performed with oral enzalutamide, which is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). METHODS:A parallel-treatment design (n = 41) was used to evaluate the effects of a strong cytochrome P450 (CYP) 2C8 inhib...

journal_title：Clinical pharmacokinetics

authors： Gibbons JA,de Vries M,Krauwinkel W,Ohtsu Y,Noukens J,van der Walt JS,Mol R,Mordenti J,Ouatas T

更新日期：2015-10-01 00:00:00

abstract：:Sulphonylureas have remained the mainstay of oral therapy for type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). They stimulate insulin release from pancreatic beta cells. Pharmacokinetic differences between the various sulphonylureas are of clinical importance in terms of the time to onset of action, timing of...

journal_title：Clinical pharmacokinetics

authors： Melander A,Donnelly R,Rydberg T

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND AND AIMS:In this study, we evaluate the performance of allometric concepts to predict the implications of age and size on the pharmacokinetics of lamotrigine, and assess the dose rationale across different age groups from 0.2 to 91 years. METHODS:An allometrically scaled pharmacokinetic model was developed ...

journal_title：Clinical pharmacokinetics

authors： van Dijkman SC,de Jager NCB,Rauwé WM,Danhof M,Della Pasqua O

更新日期：2018-08-01 00:00:00